Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferon

Robyn M Hatley, H. Sabio, Charles G Howell, F. Flickinger, R. A. Parrish

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Giant vascular neoplasms in neonates generally require aggressive medical or surgical therapy for treatment of complications. Steroids, chemotherapy, embolization, radiation, and surgery have all been used with short-term beneficial and sometimes unknown long-term side effects. A new modality of treatment, α-interferon, has recently been described. The majority of hemangiomas in children involtute by 8 years of age. Occasionally, hemangiomas can endanger vital structures and are associated with a consumption coagulopathy and thrombocytopenia (Kasabach-Merritt Syndrome). These hemangiomas occasionally do not respond to steroids, radiation therapy, cytotoxic drugs, or embolization. The mortality rates approach 50% in nonresponders. Alphainterferon has been used in these children with life-threatening complications of hemangiomas with relief of symptoms. This case illustrates the potential use of α-interferon in the management of giant hemangiomas in children. This emerging form of biological therapy avoids the risks of radiation therapy, embolization, and surgery with only minimal side effects.

Original languageEnglish (US)
Pages (from-to)1356-1359
Number of pages4
JournalJournal of Pediatric Surgery
Volume28
Issue number10
DOIs
StatePublished - Jan 1 1993

Fingerprint

Kasabach-Merritt Syndrome
Hemangioma
Interferons
Radiotherapy
Vascular Neoplasms
Steroids
Biological Therapy
Disseminated Intravascular Coagulation
Thrombocytopenia
Therapeutics
Newborn Infant
Radiation
Drug Therapy
Mortality
Pharmaceutical Preparations

Keywords

  • Hemangioma
  • Kasabach-Merritt syndrome
  • α-interferon

ASJC Scopus subject areas

  • Surgery
  • Pediatrics, Perinatology, and Child Health

Cite this

Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferon. / Hatley, Robyn M; Sabio, H.; Howell, Charles G; Flickinger, F.; Parrish, R. A.

In: Journal of Pediatric Surgery, Vol. 28, No. 10, 01.01.1993, p. 1356-1359.

Research output: Contribution to journalArticle

@article{6c3d14e5ff24476fad17807ef9596313,
title = "Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferon",
abstract = "Giant vascular neoplasms in neonates generally require aggressive medical or surgical therapy for treatment of complications. Steroids, chemotherapy, embolization, radiation, and surgery have all been used with short-term beneficial and sometimes unknown long-term side effects. A new modality of treatment, α-interferon, has recently been described. The majority of hemangiomas in children involtute by 8 years of age. Occasionally, hemangiomas can endanger vital structures and are associated with a consumption coagulopathy and thrombocytopenia (Kasabach-Merritt Syndrome). These hemangiomas occasionally do not respond to steroids, radiation therapy, cytotoxic drugs, or embolization. The mortality rates approach 50{\%} in nonresponders. Alphainterferon has been used in these children with life-threatening complications of hemangiomas with relief of symptoms. This case illustrates the potential use of α-interferon in the management of giant hemangiomas in children. This emerging form of biological therapy avoids the risks of radiation therapy, embolization, and surgery with only minimal side effects.",
keywords = "Hemangioma, Kasabach-Merritt syndrome, α-interferon",
author = "Hatley, {Robyn M} and H. Sabio and Howell, {Charles G} and F. Flickinger and Parrish, {R. A.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/S0022-3468(05)80327-6",
language = "English (US)",
volume = "28",
pages = "1356--1359",
journal = "Journal of Pediatric Surgery",
issn = "0022-3468",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Successful management of an infant with a giant hemangioma of the retroperitoneum and Kasabach-Merritt Syndrome with α-interferon

AU - Hatley, Robyn M

AU - Sabio, H.

AU - Howell, Charles G

AU - Flickinger, F.

AU - Parrish, R. A.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Giant vascular neoplasms in neonates generally require aggressive medical or surgical therapy for treatment of complications. Steroids, chemotherapy, embolization, radiation, and surgery have all been used with short-term beneficial and sometimes unknown long-term side effects. A new modality of treatment, α-interferon, has recently been described. The majority of hemangiomas in children involtute by 8 years of age. Occasionally, hemangiomas can endanger vital structures and are associated with a consumption coagulopathy and thrombocytopenia (Kasabach-Merritt Syndrome). These hemangiomas occasionally do not respond to steroids, radiation therapy, cytotoxic drugs, or embolization. The mortality rates approach 50% in nonresponders. Alphainterferon has been used in these children with life-threatening complications of hemangiomas with relief of symptoms. This case illustrates the potential use of α-interferon in the management of giant hemangiomas in children. This emerging form of biological therapy avoids the risks of radiation therapy, embolization, and surgery with only minimal side effects.

AB - Giant vascular neoplasms in neonates generally require aggressive medical or surgical therapy for treatment of complications. Steroids, chemotherapy, embolization, radiation, and surgery have all been used with short-term beneficial and sometimes unknown long-term side effects. A new modality of treatment, α-interferon, has recently been described. The majority of hemangiomas in children involtute by 8 years of age. Occasionally, hemangiomas can endanger vital structures and are associated with a consumption coagulopathy and thrombocytopenia (Kasabach-Merritt Syndrome). These hemangiomas occasionally do not respond to steroids, radiation therapy, cytotoxic drugs, or embolization. The mortality rates approach 50% in nonresponders. Alphainterferon has been used in these children with life-threatening complications of hemangiomas with relief of symptoms. This case illustrates the potential use of α-interferon in the management of giant hemangiomas in children. This emerging form of biological therapy avoids the risks of radiation therapy, embolization, and surgery with only minimal side effects.

KW - Hemangioma

KW - Kasabach-Merritt syndrome

KW - α-interferon

UR - http://www.scopus.com/inward/record.url?scp=0027482740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027482740&partnerID=8YFLogxK

U2 - 10.1016/S0022-3468(05)80327-6

DO - 10.1016/S0022-3468(05)80327-6

M3 - Article

VL - 28

SP - 1356

EP - 1359

JO - Journal of Pediatric Surgery

JF - Journal of Pediatric Surgery

SN - 0022-3468

IS - 10

ER -